Loading patent…
AssigneePhp Biotech International Inc.
InventorsMoacyr Ramos BIGHETTI, Patricia Heloise Alves BEZERRA
Estimating the term…
The present disclosure relates to bioactive peptides, compositions, production processes and uses of bioactive peptides based on snake venom as anti-tumoral agents. The disclosed bioactive peptides are synthesized based on the C-terminal of the Crotoxin B and its derivatives. The disclosed peptides demonstrate a lessened toxic effect and an elevated anti-tumoral activity against tumor cells, but specifically against triple-negative breast cancer cells, as compared to current standard care. Therefore, the disclosed bioactive snake venom peptides derived from Crotoxin are for the modulation of cellular proliferation, apoptosis, necrosis and the cycle progression of the tumor cells, especially in the triple negative breast cancer cells, presenting a suitable alternative for the sole or complementary treatment of patients with aggressive solid tumors.
A bioactive synthetic peptide derived from the C-terminal portion of the Crotoxin B snake venom toxin having anti-tumoral activity against aggressive solid tumors and little to no toxic effect over benign cells.
A method of making a bioactive peptide selected from the group consisting of SEQ ID 1, SEQ ID 2, SEQ ID 3, SEQ ID 4, SEQ ID 5, SEQ ID 6, SEQ ID 7, SEQ ID 8, SEQ ID 9, SEQ ID 10 or any combinations thereof, the method comprising the following steps:
A method of treating a solid tumor is selected from the group consisting of lung, prostate, eye cancer (ocular melanoma), colorectal, skin, brain, pancreas, kidney, breast or any combinations thereof, the method comprising administering a therapeutically effective amount of a bioactive peptide selected from the group consisting of SEQ ID 1, SEQ ID 2, SEQ ID 3, SEQ ID 4, SEQ ID 5, SEQ ID 6, SEQ ID 7, SEQ ID 8, SEQ ID 9, SEQ ID 10 or any combinations thereof in a pharmaceutically acceptable carrier to a patient.
Dependencies are inferred from the claim text.